Article:Smith, IL, Brown, S orcid.org/0000-0002-1840-3786, Nixon, J orcid.org/0000-0003-1705-7698 et al. (11 more authors) (2017) Treatment of severe, chronic hand eczema. Results from a UK-wide survey. Clinical and Experimental Dermatology, 42 (2). pp. [185][186][187][188] https://doi.org/10.1111/ced.13015 © 2016 British Association of Dermatologists. This is the peer reviewed version of the following article: "Smith, I. L., Brown, S., Nixon, J., Cowdell, F. C., Ersser, S., Fernandez, C., Goodfield, M., Green, C. M., Hampton, P., Lear, J. T., Smith, C. H., Sunderland, L., Tubeuf, S. and Wittmann, M. (2017)
ReuseUnless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version -refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.
TakedownIf you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
AbstractTreatment of severe hand eczema (HE) which is resistant to topical potent corticosteroid treatment is challenging. In 2013 we surveyed 194 UK dermatologists to obtain information about usual treatment pathways to inform the choice of the comparator in a trial of alitretinoin in severe HE (ALPHA trial); the results indicate that treatment approaches differ among UK dermatologists. Psoralen combined with ultraviolet A (PUVA) and alitretinoin were identified as the most frequent first line treatment options for hyperkeratotic HE, whereas oral corticosteroids were identified as frequent first line treatment for vesicular HE, followed by PUVA and alitretinoin. In terms of potential side effects of long-term or repeated use, oral steroids and ciclosporin A were reported to cause most concerns. There is uncertainty about which treatment gives the best short and long-term outcome due to a lack of definitive randomised controlled trials evaluating the effectiveness of different treatment pathways in severe HE.
